TRIPLE NEGATIVE BREAST CANCER (TNBC)
Clinical trials for TRIPLE NEGATIVE BREAST CANCER (TNBC) explained in plain language.
Never miss a new study
Get alerted when new TRIPLE NEGATIVE BREAST CANCER (TNBC) trials appear
Sign up with your email to follow new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood test trial aims to catch breast Cancer's return before scans can
Disease control Recruiting nowThis study is for people with a high-risk type of breast cancer who have had surgery but still have some cancer cells left. Researchers want to see if a special blood test can find signs that the cancer is coming back before it shows up on standard scans. If the blood test is pos…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 19:56 UTC
-
New pill targets immune system to fight tough cancers
Disease control Recruiting nowThis is a first-in-human study testing a new oral drug called NX-1607 in adults with advanced cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the body handles the drug, both alone and combined with a common chemot…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Apr 01, 2026 19:56 UTC
-
New Two-Pronged attack on tough breast cancer shows promise
Disease control Recruiting nowThis study is testing a new strategy for treating early-stage triple-negative breast cancer, an aggressive type with fewer treatment options. Researchers want to see if using a focused ultrasound (HIFU) to destroy the tumor and an immunotherapy drug (PD-1 inhibitor) to activate t…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
AI-Designed drug trial seeks to shrink tough cancers
Disease control Recruiting nowThis study is testing a new drug called GTAEXS617 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors in cancers like head & neck, lung, pancreatic, ovarian, and bre…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for tough breast cancers: testing Next-Generation drugs when first treatments fail
Disease control Recruiting nowThis study is testing whether different antibody-drug conjugate (ADC) medications can help control advanced breast cancer in patients whose cancer has progressed despite previous ADC treatment. The trial will enroll 160 adults with metastatic breast cancer who have already receiv…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New cancer drug trial tests experimental treatment for tough tumors
Disease control Recruiting nowThis early-stage study is testing whether an experimental drug called NRM-823 is safe and can help control advanced cancers that have stopped responding to standard treatments. Researchers will give NRM-823 alone and combined with immunotherapy to about 150 adults with various so…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Normunity AccelCo, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Scientists test 'Living Drug' that hunts breast cancer cells
Disease control Recruiting nowThis study is testing a new type of treatment called CAR-NK cell therapy for people with advanced breast cancer that has stopped responding to standard treatments. Doctors will collect a patient's own natural immune cells, modify them in a lab to better recognize and attack cance…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New cancer drug enters first human trials for Tough-to-Treat tumors
Disease control Recruiting nowThis is the first study in people to test a new drug called PQ203 for advanced solid tumors, including a hard-to-treat type of breast cancer. The main goals are to check if the drug is safe and to find the best dose for future studies. About 80 adults who have run out of standard…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: ProteinQure Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
Radiation boosts immune attack on tough breast cancer
Disease control Recruiting nowThis study is looking for the best way to combine radiation therapy with immunotherapy drugs to treat advanced triple-negative breast cancer, a particularly aggressive form. It will involve 60 patients who have not yet received chemotherapy for their advanced disease. Researchers…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New 'Tumor-Seeking' radiation drug enters human trials for tough cancers
Disease control Recruiting nowThis study is testing a new type of cancer drug that delivers radiation directly to tumors by targeting a protein called Nectin-4. It aims to find a safe and effective dose for patients with advanced solid cancers who have already tried other treatments. The trial will first dete…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Major trial tests promising new treatment for aggressive breast cancer
Disease control Recruiting nowThis study is testing whether a new drug called ESG401 works better than standard chemotherapy for people with advanced triple-negative breast cancer that has spread or returned. The trial will involve 504 participants who haven't had previous treatment for their advanced cancer.…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
First human trial begins for new cancer pill targeting advanced tumors
Disease control Recruiting nowThis is the first study in people to test a new oral pill called NKT5097 for adults with advanced or metastatic solid tumors, with a focus on certain breast, ovarian, and uterine cancers. The main goals are to find a safe dose and understand the side effects. Researchers will als…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for Tough-to-Treat breast cancer: major trial tests promising drug combo
Disease control Recruiting nowThis large, late-stage study is testing whether adding an investigational drug called AK112 to standard chemotherapy works better than chemotherapy alone for people with advanced triple-negative breast cancer. It aims to see if the combination can better control the cancer and he…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope drug enters human testing for tough cancers
Disease control Recruiting nowThis early-stage study is testing a new oral medication called JAB-2485 in adults with advanced solid tumors that have stopped responding to standard treatments. Researchers will first determine the safest dose and then look for early signs that the drug can shrink tumors in spec…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Targeted radiation therapy tested for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing a two-part approach for people with advanced cancers that cannot be removed by surgery. First, a special imaging scan is used to see if a tumor has a specific target. If it does, a targeted radiation treatment is given to try to control the cancer. The main …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: ITM Oncologics GmbH • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New drug trial targets aggressive breast cancer
Disease control Recruiting nowThis study is testing an experimental drug called tenalisib in people with advanced triple-negative breast cancer that has spread to other parts of the body. The trial will enroll 40 patients who have already tried 1-3 chemotherapy treatments. Researchers want to see if the drug …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Rhizen Pharmaceuticals SA • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New hope for Tough-to-Treat breast cancer: early trial tests promising drug
Disease control Recruiting nowThis study is testing a new drug called MR001 for people with advanced triple-negative breast cancer that has continued to grow despite previous treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early signs …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Majory Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
New hope for aggressive breast cancer: trial tests powerful drug combo before surgery
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug called QL1706 to standard chemotherapy works better when given before surgery for triple-negative breast cancer. It will involve 30 patients with stage II or III cancer who have not yet started treatment. The main goal…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Affiliated Hospital of Nantong University • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC
-
Scientists test 'Switchable' cell therapy to fight advanced breast cancer
Disease control Recruiting nowThis is an early study to test the safety of a new two-part treatment for people with advanced breast cancer that has spread or cannot be removed by surgery. The treatment involves giving patients their own modified immune cells (CLBR001), followed by a biologic drug (ABBV-461) t…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Mar 09, 2026 14:24 UTC
-
New hope for advanced cancer patients as experimental drug trial begins
Disease control Recruiting nowThis is the first study in people to test a new drug called XB010 for advanced solid tumors. The main goals are to find a safe dose and see how the body handles the drug, both by itself and when combined with another cancer therapy. It is for adults with certain advanced cancers …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Feb 23, 2026 14:51 UTC
-
Scientists collect cancer patients' cells for future 'living drug' therapy
Knowledge-focused Recruiting nowThis study aims to collect tumor tissue and blood cells from people with advanced solid tumors to prepare for future CAR T-cell therapy. Researchers will analyze the cancer tissue to understand how tumors hide from the immune system and collect participants' own immune cells thro…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Mar 19, 2026 14:55 UTC